CN120441548A - Cereblon结合化合物、其组合物及其用于治疗的方法 - Google Patents

Cereblon结合化合物、其组合物及其用于治疗的方法

Info

Publication number
CN120441548A
CN120441548A CN202510574007.2A CN202510574007A CN120441548A CN 120441548 A CN120441548 A CN 120441548A CN 202510574007 A CN202510574007 A CN 202510574007A CN 120441548 A CN120441548 A CN 120441548A
Authority
CN
China
Prior art keywords
trans
trifluoromethyl
cyclohexyl
dimethyl
oxo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202510574007.2A
Other languages
English (en)
Chinese (zh)
Inventor
M·D·亚历山大
M·D·科雷亚
D·达尔维
V·H·S·格兰特
J·汉森
R·L·哈里斯三世
E·J·霍恩
D·黄
C·梅恩
S·诺里斯
V·普兰特文-克雷尼茨基
J·J·萨皮恩扎
L·特赫拉尼
B·W·怀特菲尔德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Xinji
Original Assignee
Xinji
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xinji filed Critical Xinji
Publication of CN120441548A publication Critical patent/CN120441548A/zh
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Cephalosporin Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
CN202510574007.2A 2020-06-24 2021-06-23 Cereblon结合化合物、其组合物及其用于治疗的方法 Pending CN120441548A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063043555P 2020-06-24 2020-06-24
US63/043,555 2020-06-24
PCT/US2021/038618 WO2021262810A1 (en) 2020-06-24 2021-06-23 Cereblon binding compounds, compositions thereof, and methods of treatment therewith
CN202180044295.0A CN115835866B (zh) 2020-06-24 2021-06-23 Cereblon结合化合物、其组合物及其用于治疗的方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN202180044295.0A Division CN115835866B (zh) 2020-06-24 2021-06-23 Cereblon结合化合物、其组合物及其用于治疗的方法

Publications (1)

Publication Number Publication Date
CN120441548A true CN120441548A (zh) 2025-08-08

Family

ID=79032408

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202510574007.2A Pending CN120441548A (zh) 2020-06-24 2021-06-23 Cereblon结合化合物、其组合物及其用于治疗的方法
CN202180044295.0A Active CN115835866B (zh) 2020-06-24 2021-06-23 Cereblon结合化合物、其组合物及其用于治疗的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202180044295.0A Active CN115835866B (zh) 2020-06-24 2021-06-23 Cereblon结合化合物、其组合物及其用于治疗的方法

Country Status (17)

Country Link
US (3) US11634407B2 (https=)
EP (1) EP4171566A4 (https=)
JP (2) JP7781792B2 (https=)
KR (1) KR20230027066A (https=)
CN (2) CN120441548A (https=)
AR (1) AR122723A1 (https=)
AU (1) AU2021296833A1 (https=)
BR (1) BR112022025933A2 (https=)
CA (1) CA3182325A1 (https=)
CL (1) CL2022003719A1 (https=)
CO (1) CO2022018653A2 (https=)
IL (1) IL299256A (https=)
MX (1) MX2022015757A (https=)
PE (1) PE20231746A1 (https=)
SA (1) SA522441857B1 (https=)
TW (1) TW202216680A (https=)
WO (1) WO2021262810A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020405129A1 (en) 2019-12-19 2022-06-23 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of androgen receptor
CR20220630A (es) 2020-05-09 2023-01-23 Arvinas Operations Inc Métodos para fabricar un compuesto bifuncional, formas ultrapuras del compuesto bifuncional y formas de dosificación que comprenden el mismo
JP7778095B2 (ja) 2020-06-24 2025-12-01 セルジーン コーポレーション セレブロン結合化合物、その組成物及びそれによる治療方法
KR20230027214A (ko) 2020-06-24 2023-02-27 셀진 코포레이션 세레블론 결합 화합물, 이의 조성물, 및 이에 의한 치료 방법
KR20230027066A (ko) 2020-06-24 2023-02-27 셀진 코포레이션 세레블론 결합 화합물, 이의 조성물, 및 이에 의한 치료 방법
CN117561249A (zh) * 2021-06-25 2024-02-13 细胞基因公司 Cereblon结合化合物、其组合物及其用于治疗的方法
EP4584259A1 (en) 2022-09-09 2025-07-16 Innovo Therapeutics, Inc. Ck1alpha and dual ck1alpha / gspt1 degrading compounds
WO2025063888A1 (en) 2023-09-19 2025-03-27 Kancure Pte. Ltd. Survivin-targeted compounds
TW202535392A (zh) 2023-12-08 2025-09-16 美商亞文納營運公司 使用雄性素受體降解劑治療脊髓延髓性肌肉萎縮
WO2025179161A1 (en) 2024-02-21 2025-08-28 Innovo Therapeutics, Inc. Protein degrading compounds

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101032483B (zh) * 2006-03-09 2011-05-04 陈德桂 调节雄激素受体活性的乙内酰脲衍生物及其应用
JP6817962B2 (ja) * 2015-01-20 2021-01-20 アルビナス・オペレーションズ・インコーポレイテッドArvinas Operations, Inc. ターゲティングされたアンドロゲン受容体分解のための化合物および方法
CN109641874A (zh) * 2016-05-10 2019-04-16 C4医药公司 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体
CN110023297A (zh) * 2016-07-08 2019-07-16 詹森药业有限公司 作为雄性激素受体拮抗剂的取代的乙内酰脲和硫代己内酰脲衍生物
CN110769822A (zh) * 2017-06-20 2020-02-07 C4医药公司 用于蛋白降解的n/o-连接的降解决定子和降解决定子体
WO2020051260A1 (en) * 2018-09-05 2020-03-12 University Of Tennessee Research Foundation Selective androgen receptor degrader (sard) ligands and methods of use thereof
CN113473987B (zh) 2018-12-19 2024-09-03 细胞基因公司 被取代的3-((3-氨基苯基)氨基)哌啶-2,6-二酮化合物、其组合物和使用其的治疗方法
CN113453681B (zh) 2018-12-19 2024-10-11 细胞基因公司 经取代的3-((3-氨基苯基)氨基)哌啶-2,6-二酮化合物、其组合物及使用它们的治疗方法
JP7778095B2 (ja) 2020-06-24 2025-12-01 セルジーン コーポレーション セレブロン結合化合物、その組成物及びそれによる治療方法
KR20230027214A (ko) 2020-06-24 2023-02-27 셀진 코포레이션 세레블론 결합 화합물, 이의 조성물, 및 이에 의한 치료 방법
KR20230027066A (ko) 2020-06-24 2023-02-27 셀진 코포레이션 세레블론 결합 화합물, 이의 조성물, 및 이에 의한 치료 방법

Also Published As

Publication number Publication date
AR122723A1 (es) 2022-09-28
US20250188056A1 (en) 2025-06-12
CA3182325A1 (en) 2021-12-30
EP4171566A4 (en) 2024-07-24
SA522441857B1 (ar) 2024-07-21
PE20231746A1 (es) 2023-11-06
US20210403454A1 (en) 2021-12-30
US20230242509A1 (en) 2023-08-03
IL299256A (en) 2023-02-01
US11634407B2 (en) 2023-04-25
JP7781792B2 (ja) 2025-12-08
JP2026035702A (ja) 2026-03-04
WO2021262810A1 (en) 2021-12-30
CN115835866B (zh) 2025-05-02
KR20230027066A (ko) 2023-02-27
AU2021296833A1 (en) 2023-01-19
CL2022003719A1 (es) 2023-05-12
JP2023533203A (ja) 2023-08-02
MX2022015757A (es) 2023-01-19
US12103920B2 (en) 2024-10-01
EP4171566A1 (en) 2023-05-03
CN115835866A (zh) 2023-03-21
TW202216680A (zh) 2022-05-01
CO2022018653A2 (es) 2023-03-27
BR112022025933A2 (pt) 2023-01-10

Similar Documents

Publication Publication Date Title
CN115835866B (zh) Cereblon结合化合物、其组合物及其用于治疗的方法
US12404241B2 (en) Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith
CN115955979B (zh) Cereblon结合化合物、其组合物及其用于治疗的方法
CN115968293B (zh) Cereblon结合化合物、其组合物及其用于治疗的方法
BR112021012186A2 (pt) Compostos de 3-((3-aminofenil)amino)piperidina-2,6-diona substituídos, composições dos mesmos e métodos de tratamento com os mesmos
CN117561249A (zh) Cereblon结合化合物、其组合物及其用于治疗的方法
CN117545752A (zh) Cereblon结合化合物、其组合物及其用于治疗的方法
EA047871B1 (ru) Соединения, связывающие цереблон, композиции на их основе и способы лечения с их применением
HK40091357B (en) Cereblon binding compounds, compositions thereof, and methods of treatment therewith
HK40091357A (en) Cereblon binding compounds, compositions thereof, and methods of treatment therewith
HK40061385A (en) Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith
HK40061385B (en) Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination